CONTEXT: Rising aminotransferases (ATs) [either aspartate aminotransferase (AST) or alanine aminotransferase (ALT) are one of the first signs of hepatotoxicity following acetaminophen (APAP)] overdose (OD). However, the timing and speed of such rises are not well characterized, hampering early risk prediction. OBJECTIVE: To describe the kinetics of AT release in acute APAP OD patients who develop hepatotoxicity despite treatment. METHODS: A descriptive study of acute APAP OD patients with peak AT > 1,000 IU/L taken from the derivation subset of the Canadian Acetaminophen Overdose Study (CAOS), a large, multicenter retrospective cohort of patients hospitalized for APAP poisoning. RESULTS: Of 2,488 hospital admissions for acute APAP OD, 94 met inclusion criteria. Treatment with acetylcysteine, mostly intravenously, was begun in all cases within 24 h of ingestion. The initial AT concentration was already elevated in most patients at presentation [median 211 (IQR 77-511) IU/L obtained at 15.3 (12.1-19.2) h postingestion], and exceeded 100 IU/L in almost all patients within 24 h of ingestion. Serum AT concentrations rose rapidly [doubling time 9.5 h (95% CI: 8.7-10.4 h)], especially in patients who developed AT > 1,000 IU/L within 48 h of ingestion. Coagulopathy was worse in these patients and in those with an AT > 250 IU/L during the first 12 h of treatment with acetylcysteine. DISCUSSION AND CONCLUSIONS: An abnormal and rapidly doubling AT at presentation is more typical in severely poisoned patients, as judged by the effects on clotting. These data suggest that risk prediction instruments may be improved by incorporating both the serum AT concentration at initiation of antidotal therapy and its rate of change. Further studies using such an approach are warranted.
CONTEXT: Rising aminotransferases (ATs) [either aspartate aminotransferase (AST) or alanine aminotransferase (ALT) are one of the first signs of hepatotoxicity following acetaminophen (APAP)] overdose (OD). However, the timing and speed of such rises are not well characterized, hampering early risk prediction. OBJECTIVE: To describe the kinetics of AT release in acute APAP OD patients who develop hepatotoxicity despite treatment. METHODS: A descriptive study of acute APAP OD patients with peak AT > 1,000 IU/L taken from the derivation subset of the Canadian AcetaminophenOverdose Study (CAOS), a large, multicenter retrospective cohort of patients hospitalized for APAPpoisoning. RESULTS: Of 2,488 hospital admissions for acute APAP OD, 94 met inclusion criteria. Treatment with acetylcysteine, mostly intravenously, was begun in all cases within 24 h of ingestion. The initial AT concentration was already elevated in most patients at presentation [median 211 (IQR 77-511) IU/L obtained at 15.3 (12.1-19.2) h postingestion], and exceeded 100 IU/L in almost all patients within 24 h of ingestion. Serum AT concentrations rose rapidly [doubling time 9.5 h (95% CI: 8.7-10.4 h)], especially in patients who developed AT > 1,000 IU/L within 48 h of ingestion. Coagulopathy was worse in these patients and in those with an AT > 250 IU/L during the first 12 h of treatment with acetylcysteine. DISCUSSION AND CONCLUSIONS: An abnormal and rapidly doubling AT at presentation is more typical in severely poisoned patients, as judged by the effects on clotting. These data suggest that risk prediction instruments may be improved by incorporating both the serum AT concentration at initiation of antidotal therapy and its rate of change. Further studies using such an approach are warranted.
Authors: Jeanine Ward; Chitra Kanchagar; Isana Veksler-Lublinsky; Rosalind C Lee; Mitchell R McGill; Hartmut Jaeschke; Steven C Curry; Victor R Ambros Journal: Proc Natl Acad Sci U S A Date: 2014-08-04 Impact factor: 11.205
Authors: Abel Felipe Freitag; Gabriel Fernando Esteves Cardia; Bruno Ambrósio da Rocha; Rafael Pazzinatto Aguiar; Francielli Maria de Souza Silva-Comar; Ricardo Alexandre Spironello; Renata Grespan; Silvana Martins Caparroz-Assef; Ciomar Aparecida Bersani-Amado; Roberto Kenji Nakamura Cuman Journal: Evid Based Complement Alternat Med Date: 2015-03-02 Impact factor: 2.629
Authors: Alexandre Nuzzo; Shireen Salem; Isabelle Malissin; Abdourahmane Diallo; Nicolas Deye; Antoine Goury; Hervé Gourlain; Nicolas Péron; Eric Vicaut; Sebastian Voicu; Bruno Mégarbane Journal: United European Gastroenterol J Date: 2021-06 Impact factor: 4.623